IVD Quality Control Market (2024-2031)
The IVD Quality Control Market was valued at $1.63 billion in 2023. This market is expected to reach $2.28 billion by 2031, from an estimated $1.7 billion in 2024, at a CAGR of 4.3% during the forecast period 2024-2031. IVD Quality Control Market Size & Forecast The IVD quality control market covers
- Published
- Jan 2024
- Pages
- 267
- Format
- PDF + Excel
- Report ID
- MRHC - 104119
- Base year
- 2023
- 2023 · BASELINE
- $1.63B
- 2031
- $2.28B
- CAGR 2024–2031
- 4.3%
2023 baseline · 2024–2031 forecast at 4.3% CAGR · hover a bar for the value
Key highlights
By Offering: In 2024, the Quality Control Products Segment is Expected to Dominate IVD Quality Controls Market
Based on Technology: In 2024, the Immunoassay/Immunochemistry Segment is Expected to Dominate IVD Quality Controls Market
Based on Applications: In 2024, the Infectious Diseases Segment is Expected to Dominate IVD quality controls Market
Based on End User: In 2024, the Hospitals & Clinics Segment Expected to Dominate IVD quality controls Market
Report summary
| Particulars | Details |
|---|---|
| Page No | 267 |
| Format | |
| Forecast Period | 2024-2031 |
| Base Year | 2023 |
| CAGR | 4.3% |
| Market Size (Value) | USD 2.28 billion by 2031 |
| Segments Covered | By Offering · Quality Control Products · Quality Control Products, by Type · Serum/Plasma-based Controls · Whole Blood-based Controls · Urine-based Controls · Other Controls · Quality Control Products, by Function · Independent Controls · Instrument-Specific Controls · Quality Assessment Services · Data Management Solutions · (Notes: Other controls include saliva-based controls, cerebrospinal fluid-based, and protein controls.) · By Technology · Immunoassay/Immunochemistry · Biochemistry/Clinical Chemistry · Molecular Diagnostics · Hematology · Coagulation/Hemostasis · Microbiology · Other Technologies · (Notes: Other technologies include histochemistry, urinalysis, and whole-blood glucose monitoring) · By Application · Infectious Diseases · Oncology · Cardiology · Autoimmune Disorders · Neurology · Other Applications · (Notes: Other applications include pregnancy and fertility testing, drug abuse testing, diabetes, genetic disorders, and trace elements testing) · By End User · Hospitals & Clinics · Diagnostic Laboratories · Academic Institutes & Research Laboratories · Other End Users · (Notes: Other end users include home care, nursing homes, ambulatory care centers, and transfusion laboratories.) |
| Countries Covered | North America (U.S., Canada), Europe (Germany, France, Italy, U.K., Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East & Africa |
| Key Companies | Seimens Healthineers AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), LGC Group (U.K.), Thermo Fisher Scientific Inc. (U.S.), SERO AS (Norway), Randox Laboratories Ltd. (U.K.), QuidelOrtho Corporation (U.S.), Streck LLC (U.S.), and Microbiologics, Inc. (U.S.). |
Report overview
Segments covered: offering, quality control product, type, serum/plasma-based control, whole blood-based control, urine-based control, other control, function, independent control, instrument-specific control, quality assessment service, data management solution, technology, immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostic, hematology, coagulation/hemostasis, microbiology, other technology, application, infectious disease, oncology, cardiology, autoimmune disorder, neurology, other application, end user, hospitals & clinic, diagnostic laboratory, academic institutes & research laboratory, other end user. Regions: North America, Europe, Asia-Pacific, Latin America.
The IVD quality control market covers quality control products, external quality assessment services, and data management solutions offered by companies for infectious diseases, cardiology, hematology, oncology, and other applications for use in hospitals & clinics, diagnostic laboratories, academic & research institutes, and blood banks.
The rising prevalence of chronic diseases, coupled with the increasing geriatric population, growing demand for third-party quality controls, need for internal and external quality assessment reports, increasing number of clinical laboratories, and growing demand for Point-of-Care (POC) and rapid diagnostics drive the market growth. However, stringent technical requirements and regulatory processes for quality controls restrain this market's growth.
Report infographic
Market dynamics
3 factors across 2 forcesGrowing Demand for Multi-analyte and Multi-instrument Controls
Among the IVD quality controls commercially available, there is an increasing demand for multi-analyte and multi-instrument controls. Multi-analyte controls are designed to contain multiple analytes of interest, representing a range of concentrations typically found in patient samples. On the other hand, multi-instrument controls are designed to be compatible with different types of laboratory instruments and testing platforms.
There is an increasing demand for multi-analyte controls as they eliminate the need to use separate controls for each analyte, streamlining the quality control process and saving time and resources. They are also cost-effective, as consolidating multiple analytes into a single control can be more cost-effective than purchasing separate controls for each analyte. Overall, the demand for multi-analyte and multi-instrument controls is driven by the need for efficient, cost-effective, and standardized quality control processes in diagnostic testing.
Need for Internal and External Quality Assessment Reports
Both the internal and external quality assessment reports are required due to several reasons. Quality Assessment (QA) reports provide a systematic evaluation of the laboratory's performance by monitoring the accuracy and precision of test results. These reports ensure that the laboratory consistently produces reliable results. Internal QA reports contribute to meeting regulatory standards and accreditation requirements. These reports demonstrate the laboratory's commitment to quality and compliance with established guidelines. By analyzing internal QA data, laboratories can identify trends, patterns, and potential sources of error. This information facilitates targeted process improvements, leading to enhanced testing procedures and reduced chances of errors. Whereas external QA reports enable laboratories to compare their results with those of other facilities. Discrepancies can identify areas for improvement and prompt corrective actions. Moreover, participation in external QA programs is often a requirement for laboratory accreditation. Proficiency testing through external QA helps laboratories maintain their accreditation status. External QA reports validate the accuracy of a laboratory's testing methods and verify its ability to generate reliable results. These assessment data are analyzed using quality controls, hence driving the market growth.
Table of contents
12 chapters · 130 sections · 267 pages · click to expandSegmental analysis
| Segment | Largest share (2024) | Fastest growth (2024–2031) |
|---|---|---|
| By Offering | Quality Control Products | Quality control products |
| By Technology | Immunoassay/Immunochemistry | — |
| By Application | Infectious Diseases | — |
| By End User | Hospitals & Clinics Segment Expected | — |
By Offering
- The quality control products segment is segmented into quality control products, quality assessment services, and data management solutions.
- The quality control products segment is expected to account for the largest share of 77.4% of the IVD quality control market.
- The large market share of this segment is attributed to the wide availability of controls for various applications.
- Also, advancements in these controls have expanded their utilization.
- For instance, in February 2020, Bio-Rad Laboratories, Inc. (U.S.) launched EDX RP Positive Run Control for clinical respiratory assays.
- It contains 22 respiratory analytes.
- Furthermore, the quality control products segment is projected to witness the highest growth rate of 4.4% during the forecast period of 2024–2031.
By Technology
- The Immunoassay/Immunochemistry Segment is Expected to Dominate IVD Quality Controls Market
- The quality control products segment is segmented into immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, hematology, coagulation/hemostasis, microbiology, and other technologies.
- Immunoassay/immunochemistry segment is expected to account for the largest share of 32.8% the IVD quality control market.
- The increasing use of immunoassays in POC & infectious disease testing, development of novel tests, increasing usage of miniaturized devices, and rising demand for immunoassay-based tests are expected to support the segment’s largest share.
- For instance, in February 2021, Agilent Technologies Inc. (U.S.) launched Agilent Dako SARS-CoV-2 IgG, an immunoassay kit to detect SARS-CoV-2 IgG antibodies.
By Application
- The quality control products segment is segmented into infectious diseases, oncology, cardiology, autoimmune disorders, neurology, and other applications.
- The infectious diseases segment is expected to account for the largest share of the IVD quality control market.
- There has been an increasing prevalence of infectious diseases globally.
- According to a 2022 article published by Families Fighting Flu, Inc. (U.S.), an estimated 1 billion people worldwide are infected by seasonal influenza every year, of which 3-5 million people have a severe case of flu.
- Moreover, according to the WHO, a total of 1.6 million people died from TB in 2021 globally (out of which 187,000 were HIV patients).
- Hence, the higher adoption of sensitive and cost-effective tests to diagnose increasing infectious diseases resulted in an increased demand for IVD quality controls for infectious diseases.
By End User
- The quality control products segment is segmented into hospitals & clinics, diagnostics laboratories, academic & research institutes, and blood banks.
- The hospitals & clinics segment is expected to account for the largest share of the IVD quality control market.
- The largest share of this segment is mainly attributed to the large share of diagnostics tests performed in the hospital-attached laboratories and the relatively higher demand for quality controls in these healthcare settings to ensure the accuracy and reliability of IVD test results of the patients.
- Additionally, during COVID-19, hospital admissions increased, which further led to the adoption of COVID-19 test quality controls in hospitals & clinics.
Geographic analysis
North America
Largest shareIn 2024, North America is expected to account for the largest share of the 38.2% global IVD quality control market. The large market share of this region is attributed to the rising prevalence of chronic and infectious diseases, increasing awareness regarding early disease diagnosis, advanced diagnostics infrastructure, a large number of laboratory tests performed annually, the mandatory quality assessments of laboratories, and the participation of laboratories in external quality assessment programs. North America to Dominate the Market in 2024
Asia-Pacific
Fastest growthMoreover, the market in Asia-Pacific is slated to register the highest growth rate of 5.4% during the forecast period. The rising population of the country, the increasing prevalence of disorders such as diabetes and HIV, the growth in the number of medical laboratories to increase the testing capacity of the patients and the focus of the country toward the quality assurance standards of these medical laboratories are some of the factors diving the demand for IVD quality control in China.
Competitive landscape
- May 2023
Maine enhanced the VALIDATE CM2 by adding Troponin I for the Roche cobas platform.
- November 2022
Bio-Rad Laboratories launched independent quality control products, including InteliQ and Liquichek compact vials for Abbott Alinity ci-series integrated clinical chemistry and immunoassay testing instruments.
- July 2021
Thermo Fisher partnered with Ortho Clinical Diagnostics (U.S.) to supply MAS Quality Controls and LabLink xL Quality Assurance Software to Ortho.
- Seimens Healthineers AG · Germany
- Bio-Rad Laboratories, Inc. (U.S.)
- Danaher Corporation (U.S.)
- LGC Group (U.K.)
- Thermo Fisher Scientific Inc. (U.S.)
- SERO AS · Norway
- Randox Laboratories Ltd. (U.K.)
- QuidelOrtho Corporation (U.S.)
- Streck LLC (U.S.)
- Microbiologics, Inc. (U.S.)
Frequently asked questions
This study covers quality control products, quality assessment services, and data management solutions applied in hospitals & clinics, diagnostic laboratories, academic institutes & research laboratories, and other end users.
Cite this report
Meticulous Research. (2024). IVD Quality Control Market - Global Opportunity Analysis and Industry Forecast (2024-2031) (Report No. MRHC - 104119). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/ivd-quality-control-market-3447